## CITATION REPORT List of articles citing

Nivolumab + low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142

DOI: 10.1016/j.annonc.2022.06.008 Annals of Oncology, 2022, , .

Source: https://exaly.com/paper-pdf/148933413/citation-report.pdf

Version: 2024-04-10

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
19	Deficient mismatch repair/microsatellite unstable colorectal cancer: Diagnosis, prognosis and treatment. <b>2022</b> , 175, 136-157		5
18	Distinct pre-treatment innate immune landscape and post-treatment T cell responses underlie immunotherapy-induced colitis.		O
17	Biomarkers in Metastatic Colorectal Cancer: Status Quo and Future Perspective. <b>2022</b> , 14, 4828		3
16	Long-term benefit of immunotherapy in a patient with squamous lung cancer exhibiting mismatch repair deficient/high microsatellite instability/high tumor mutational burden: A case report and literature review. 13,		O
15	Neoadjuvant Pembrolizumab in Localized Microsatellite Instability High/Deficient Mismatch Repair Solid Tumors.		1
14	Harnessing the therapeutic vulnerability of MMR heterogeneity in colorectal cancer. <b>2023</b> , 4, 100908		O
13	European expert panel consensus on the clinical management of BRAF-mutant metastatic colorectal cancer. <b>2023</b> , 115, 102541		O
12	Microsatellite Instability: A Review of Molecular Epidemiology and Implications for Immune Checkpoint Inhibitor Therapy. <b>2023</b> , 15, 2288		O
11	Identification of the molecular characteristics associated with microsatellite status of colorectal cancer patients for the clinical application of immunotherapy. 14,		O
10	How to overcome resistance to immune checkpoint inhibitors in colorectal cancer: From mechanisms to translation.		0
9	Pembrolizumab for previously treated, microsatellite instabilityligh/mismatch repairleficient advanced colorectal cancer: final analysis of KEYNOTE-164. <b>2023</b> ,		O
8	Neue medikamentse Konzepte bei Patienten mit kolorektalen Karzinomen und Mikrosatelliteninstabilits.		O
7	Immunotherapy in Urological, Gynecological and Gastrointestinal Cancers Œurrent Landscape. <b>2023</b> , 112, 149-155		1
6	Systemic treatment for metastatic colorectal cancer. 29, 1425-1444		О
5	Systemic treatment for metastatic colorectal cancer. 29, 1569-1588		O
4	Treatment paradigm and prognostic factor analysis of rectal squamous cell carcinoma- a retrospective study.		0
3	PD-1/PD-L1 Inhibitor Plus Chemotherapy Versus PD-1/PD-L1 Inhibitor in Microsatellite Instability Gastrointestinal Cancers: A Multicenter Retrospective Study. <b>2023</b> ,		O

2 Checkpointinhibitoren beim kolorektalen Karzinom Leine neue La?.

О

Combinaisons dihhibiteurs de points de contrie immunitaires en oncologie : l'at de l'Ert et perspectives. 2023,

1